BGBibek Gooptu

Bibek Gooptu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bibek Gooptu has a total of 361 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Both terminal misfolding and polymerisation contribute to disease-relevant responses in cell models of α 1 -antitrypsin deficiency-associated liver disease

    by Panayiota Stylianou, Kish Adoni, Mun Peak Nyon, Adam Cryar, Imran Haq, Jennifer A. Dickens, Charis-Patricia Segeritz, Graeme C. Smith, Adriana Ordonez, James A. Irving, et al.

    Polymerisation of α 1 -antitrypsin within hepatocytes is considered central to the pathogenesis of α 1 -antitrypsin deficiency-associated liver fibrosis, most commonly in homozygotes for the Z (p.Glu342Lys) allele. Polymerisation proceeds via self-association of monomeric intermediate states. In parallel, >50% of synthesised Z α 1 -antitrypsin is instead recognized as terminally-misfolded and degraded. It is unclear whether this contributes to Z α 1 -antitrypsin deficiency-associated liver disease. We characterised the relationships between polymer formation, terminal misfolding and their cellular consequences, using label-free proteomics mass spectrometry (MS), light and electron microscopy, and cellular assays. Proteomic analyses of well-established CHO cell models of hepatocyte handling of α 1 -antitrypsin variants indicated that cellular responses to the Z mutation were surprisingly similar to those seen with the Null HongKong variant (NHK), which can only misfold terminally and cannot polymerise. A minor set of proteins showed increases associated with Z and not NHK α 1 -antitrypsin expression, consistent with a polymer-specific response, characterized by association with increased organellar organization and vesicle-mediated transport. Conversely, proteostatic and pro-fibrotic integrin-associated pathways increased with the degree of terminal misfolding of the expressed α 1 -antitrypsin variant. Bioenergetic pathway changes indicated concomitant switching from oxidative to glycolytic metabolism. Cell studies further correlated fibrosis-associated behaviours with terminal misfolding rather than polymerisation. Terminal misfolding, as well as polymerisation behaviour, may therefore be important for pro-fibrotic responses including metabolic reprogramming and senescence in Z α 1 -antitrypsin deficiency. Molecular therapies may prove most efficacious for associated liver disease if they address terminal misfolding as well as polymerisation.

  • Open Access

    Structure and function of the EDEM:PDI ERAD checkpoint complex

    by Pietro Roversi, Charlie Hitchman, Andrea Lia, Gabriela Chiritoiu, Cristian Munteanu, Juan Ortigosa, Simona Ghenea, Ikuo Wada, Maria De Benedictis, Gabor Tax, et al.

    The ERAD glycoprotein misfolding checkpoint complex de-mannosylates misfolded glycoproteins targeting them to retrotranslocation, ubiquitination, and proteasomal degradation. The complex comprises an Endoplasmic Reticulum-Degradation Enhancing α-Mannosidase (EDEM) and a Protein Disulfide Isomerase (PDI). We solved Cryo-EM structures of the Chaetomium thermophilum (Ct) EDEM:PDI complex, both by itself and in complex with a classic ERAD substrate, α1-antitrypsin (A1AT-NHK). The EDEM catalytic domain nestles within the PDI arc, while A1AT-NHK binds EDEM’s C-terminal flexible domains. Mass spectrometry reveals a disulfide bond between A1AT-NHK and an exposed Cys in the protease-associated domain of EDEM. Non-reducing SDS-PAGE analysis of protein samples from mammalian cells co-transfected with EDEM:PDI and A1AT-NHK show a shift of the EDEM:PDI band to higher molecular weight. Redox chemistry between EDEM and PDI disulfide bonds generates oxidized, demannosylation-competent EDEM and reduced PDI and primes the PDI to function as the ERAD reductase, facilitating client retrotranslocation.

  • Open Access

    Structure and function of the EDEM:PDI ERAD checkpoint complex

    by Charlie J. Hitchman, Andrea Lia, Gabriela N. Chiritoiu, Cristian V. A. Munteanu, Juan R. Ortigosa, Simona Ghenea, Christos G. Savva, Ikuo Wada, Maria De Benedictis, Gabor Tax, et al.

    The ERAD glycoprotein misfolding checkpoint complex de-mannosylates misfolded glycoproteins to enable retrotranslocation, ubiquitination, and proteasomal degradation. The complex comprises an Endoplasmic Reticulum-Degradation Enhancing α -Mannosidase (EDEM) and a Protein Disulfide Isomerase (PDI). We solved Cryo-EM structures of Chaetomium thermophilum (Ct) Ct EDEM: Ct PDI, both as the heterodimer with no client and in complex with α 1-antitrypsin (A1AT-NHK). The EDEM catalytic domain nests within the PDI arc, while A1AT-NHK binds EDEM’s C-terminal flexible domains. Mass spectrometry reveals a disulfide bond between A1AT-NHK and an exposed Cys in the PAD of the EDEM. Co-transfection of EDEM, A1AT-NHK, and PDI shifts EDEM:PDI to higher molecular weight in non-reducing SDS-PAGE. Redox chemistry between EDEM and PDI disulfide bonds generates oxidized, demannosylation-competent EDEM and reduced PDI, priming PDI to function as the ERAD reductase, facilitating client retrotranslocation.

  • Open Access

    BPF-GILD study: an observational cohort study of UK pigeon fanciers

    by Richard J Allen, Jude Wellens-Mensah, Olivia C Leavy, Stephen Bourke, Will Henderson, Howard Smith, Emma Johnson, Daniella Marks, Ye Myat, Cecillia Rafique, et al.

    Introduction Hypersensitivity pneumonitis (HP), a common interstitial lung disease (ILD), comprises two distinct but related forms, acute and fibrotic (fHP). HP is classically described as a disease triggered by antigen exposure. However, a wide range of triggers are described and in ∼50% of cases no cause is identified, rendering observational studies challenging. The British Pigeon Fanciers Genetics of ILD (BPF-GILD) study aims to address this by studying a population with a clear history of exposure to a common trigger. Methods Participants were recruited from 2019 to 2023 at large UK Pigeon Fancier meetings. Each participant performed spirometry, completed a standardised questionnaire with a doctor, and provided blood samples. We present our baseline data in this manuscript. Results 417 subjects were recruited from four shows. The median age of the cohort was 63 years, 95% were male and 94% self-reported white ethnicity. The median number of pigeons kept was 80 [range 4-800], with fanciers spending 14 hours per week [1-100] in their lofts. 52% of participants had occupational dust exposures. 49% of the cohort reported at least one respiratory symptom related to loft exposure. 14% had a history of ILD and these individuals had more loft-related respiratory symptoms, poorer lung function, and appeared more likely to wear a mask with their pigeons than those without (74% vs 57%). 41% of participants had positive responses to questions employed to detect occult connective tissue disease in ILD clinics. Discussion Our well characterised cohort of pigeon fanciers commonly experience acute HP symptoms and are likely to be at increased risk of fHP. Subsequent work using stored samples will enable us to determine genetic risk factors and pathways relevant to the development of fHP.

  • Open Access

    Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis

    by Jessica F. Calver, Nimesh R. Parmar, Gemma Harris, Ryan M. Lithgo, Panayiota Stylianou, Fredrik R. Zetterberg, Bibek Gooptu, Alison C. Mackinnon, Stephen B. Carr, Lee A. Borthwick, et al.


  • Open Access

    CD98 is critical for a conserved inflammatory response to diverse injury stimuli relevant to IPF exacerbations and COVID pneumonitis

    by Panayiota Stylianou, Sara Rushwan, Wei Wang, M. Azim Miah, Omeed Darweesh, Alison Mackinnon, Katy M. Roach, Charles J. Hitchman, Oksana Gonchar, Stephen Thorpe, et al.

    Progressive fibrosing interstitial lung diseases (PFILDs) cause substantial morbidity and mortality. Antifibrotic agents slow progression, but most of the clinical need remains unmet. The archetypal PFILD is idiopathic pulmonary fibrosis (IPF). Chronic progression is driven by transforming growth factor (TGF-)β1 signalling. It is punctuated by inflammatory flares known as acute exacerbations (AE-IPF), which are associated with accelerated decline and high mortality. We hypothesized that acute injury responses underlying exacerbations and the mechanisms of chronic fibrosis overlap at the molecular level, via a cell surface assembly nucleated by galectin-3 that we term the ‘gal-3-fibrosome’. We focused upon a putative pro-inflammatory galectin-3 ligand, the CD98:integrin complex. Our data indicate CD98 and β1-integrin co-localise with galectin-3 within epithelial cells in IPF lung tissue, and within 40 nm in human lung tissue treated with TGF-β1 compared to controls. CD98 is required for interleukin (IL-)6 and IL-8 responses to biochemical and biophysical conditions mimicking stimuli of AE-IPF in vivo , ex vivo and in cells, and for an interstitial neutrophilic response in a mouse model. We demonstrate this pathway progresses via intracellular influx of Ca 2+ mediated by TRPV4, and NF-κB activation, operating in positive feedback. Lastly we show the CD98- and galectin-3-dependence of IL-6 and IL-8 responses to the SARS-CoV-2 spike protein receptor binding domain and the conservation of this response pattern between lung epithelial cells and monocyte-derived macrophages. Taken together our findings identify CD98 as a key mediator of both pro-fibrotic and acute inflammatory responses in the lung with relevance to AE- and chronic progression of IPF, and the priming of fibrotic lungs for acute inflammatory responses. They similarly implicate CD98 and galectin-3 as mediators of COVID pneumonitis and worse outcomes in ILD patients with COVID.


  • Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency

    by Malin Fromme, Carolin V Schneider, Vitor Pereira, Karim Hamesch, Monica Pons, Matthias C Reichert, Federica Benini, Paul Ellis, Katrine H Thorhauge, Mattias Mandorfer, et al.

    Objective Alpha-1 antitrypsin deficiency (AATD) is a common, potentially lethal inborn disorder caused by mutations in alpha-1 antitrypsin (AAT). Homozygosity for the ‘Pi*Z’ variant of AAT (Pi*ZZ genotype) causes lung and liver disease, whereas heterozygous ‘Pi*Z’ carriage (Pi*MZ genotype) predisposes to gallstones and liver fibrosis. The clinical significance of the more common ‘Pi*S’ variant remains largely undefined and no robust data exist on the prevalence of liver tumours in AATD. Design Baseline phenotypes of AATD individuals and non-carriers were analysed in 482 380 participants in the UK Biobank. 1104 participants of a multinational cohort (586 Pi*ZZ, 239 Pi*SZ, 279 non-carriers) underwent a comprehensive clinical assessment. Associations were adjusted for age, sex, body mass index, diabetes and alcohol consumption. Results Among UK Biobank participants, Pi*ZZ individuals displayed the highest liver enzyme values, the highest occurrence of liver fibrosis/cirrhosis (adjusted OR (aOR)=21.7 (8.8–53.7)) and primary liver cancer (aOR=44.5 (10.8–183.6)). Subjects with Pi*MZ genotype had slightly elevated liver enzymes and moderately increased odds for liver fibrosis/cirrhosis (aOR=1.7 (1.2–2.2)) and cholelithiasis (aOR=1.3 (1.2–1.4)). Individuals with homozygous Pi*S mutation (Pi*SS genotype) harboured minimally elevated alanine aminotransferase values, but no other hepatobiliary abnormalities. Pi*SZ participants displayed higher liver enzymes, more frequent liver fibrosis/cirrhosis (aOR=3.1 (1.1–8.2)) and primary liver cancer (aOR=6.6 (1.6–26.9)). The higher fibrosis burden was confirmed in a multinational cohort. Male sex, age ≥50 years, obesity and the presence of diabetes were associated with significant liver fibrosis. Conclusion Our study defines the hepatobiliary phenotype of individuals with the most relevant AATD genotypes including their predisposition to liver tumours, thereby allowing evidence-based advice and individualised hepatological surveillance.


  • Open Access

    The structural basis for Z α 1 -antitrypsin polymerization in the liver

    by Sarah V. Faull, Emma L. K. Elliston, Bibek Gooptu, Alistair M. Jagger, Ibrahim Aldobiyan, Adam Redzej, Magd Badaoui, Nina Heyer-Chauhan, S. Tamir Rashid, Gary M. Reynolds, et al.

    α 1 -Antitrypsin polymers from human tissue have a structure most consistent with an intermolecular C-terminal domain swap.


  • Open Access

    Vitamin D (1,25(OH)2D3) induces α-1-antitrypsin synthesis by CD4+ T cells, which is required for 1,25(OH)2D3-driven IL-10

    by Sarah Dimeloe, Louise V. Rice, Hebe Chen, Charlotte Cheadle, John Raynes, Paul Pfeffer, Paul Lavender, David F. Richards, Mun Peak Nyon, James M. McDonnell, et al.


  • Open Access

    hiPSC hepatocyte model demonstrates the role of unfolded protein response and inflammatory networks in α1-antitrypsin deficiency

    by Charis-Patricia Segeritz, Sheikh Tamir Rashid, Miguel Cardoso de Brito, Maria Paola Serra, Adriana Ordonez, Carola Maria Morell, Joseph E. Kaserman, Pedro Madrigal, Nicholas R.F. Hannan, Laurent Gatto, et al.